-
1.发明授权Dosage forms comprising a CETP inhibitors and an HMG-CoA reductase inhibitor 有权包含CETP抑制剂和HMG-CoA还原酶抑制剂的剂型公开(公告)号：US07897175B2
公开(公告)日：2011-03-01
申请号：US10739567
申请日：2003-12-18
申请人： Dwayne T. Friesen , David K. Lyon , Douglas A. Lorenz , Bruno C. Hancock , Timothy J. McDermott , Ravi M. Shanker
发明人： Dwayne T. Friesen , David K. Lyon , Douglas A. Lorenz , Bruno C. Hancock , Timothy J. McDermott , Ravi M. Shanker
CPC分类号： A61K45/06 , A61K9/146 , A61K9/1652 , A61K9/2054 , A61K9/2077 , A61K9/2081 , A61K9/209 , A61K31/00 , A61K31/40 , A61K31/4706 , A61K2300/00
摘要： A dosage form comprises (1) a solid amorphous dispersion comprising a cholesterol ester transfer protein inhibitor and an acidic concentration-enhancing polymer and (2) an HMG-CoA reductase inhibitor. The solid amorphous dispersion and the HMG-CoA reductase inhibitor are combined in the dosage form so that the solid amorphous dispersion and the HMG-CoA reductase inhibitor are substantially separate from one another in the dosage form.
摘要翻译： 剂型包括（1）包含胆固醇酯转移蛋白抑制剂和酸性浓度增强聚合物的固体无定形分散体和（2）HMG-CoA还原酶抑制剂。 将固体无定形分散体和HMG-CoA还原酶抑制剂以剂型组合，使得固体无定形分散体和HMG-CoA还原酶抑制剂在剂型中基本上彼此分离。
-
公开(公告)号：US08202912B2
公开(公告)日：2012-06-19
申请号：US13208305
申请日：2011-08-11
申请人： William J. Curatolo , Ravi M. Shanker , Walter C. Babcock , Dwayne T. Friesen , James A. S. Nightingale , Douglas A. Lorenz
发明人： William J. Curatolo , Ravi M. Shanker , Walter C. Babcock , Dwayne T. Friesen , James A. S. Nightingale , Douglas A. Lorenz
CPC分类号： A61K47/38 , A61K9/146 , A61K9/1629 , A61K9/1652 , A61K31/135 , A61K31/404 , A61K31/4178 , A61K31/4375 , A61K31/496 , A61K31/517
摘要： A drug in a solubility-improved form is combined with a concentration-enhancing polymer in a sufficient amount so that the combination provides substantially enhanced drug concentration in a use environment relative to a control comprising the same amount of the same solubility-improved form of drug without the concentration-enhancing polymer.
摘要翻译： 将溶解度改善形式的药物与足够量的浓度增强聚合物组合，使得组合在使用环境中相对于包含相同量的相同溶解度改善形式的药物的对照提供了显着增强的药物浓度 没有浓度增强聚合物。
-
公开(公告)号：US08026286B2
公开(公告)日：2011-09-27
申请号：US09742785
申请日：2000-12-20
申请人： William J. Curatolo , Ravi M. Shanker , Walter C. Babcock , Dwayne T. Friesen , James A. S. Nightingale , Douglas A. Lorenz
发明人： William J. Curatolo , Ravi M. Shanker , Walter C. Babcock , Dwayne T. Friesen , James A. S. Nightingale , Douglas A. Lorenz
CPC分类号： A61K47/38 , A61K9/146 , A61K9/1629 , A61K9/1652 , A61K31/135 , A61K31/404 , A61K31/4178 , A61K31/4375 , A61K31/496 , A61K31/517
摘要： A drug in a solubility-improved form is combined with a concentration-enhancing polymer in a sufficient amount so that the combination provides substantially enhanced drug concentration in a use environment relative to a control comprising the same amount of the same solubility-improved form of drug without the concentration-enhancing polymer.
摘要翻译： 将溶解度改善形式的药物与足够量的浓度增强聚合物组合，使得组合在使用环境中相对于包含相同量的相同溶解度改善形式的药物的对照提供了显着增强的药物浓度 没有浓度增强聚合物。
-
公开(公告)号：US08501231B2
公开(公告)日：2013-08-06
申请号：US13527536
申请日：2012-06-19
申请人： William J. Curatolo , Ravi M. Shanker , Walter C. Babcock , Dwayne T. Friesen , James A. S. Nightingale , Douglas A. Lorenz
发明人： William J. Curatolo , Ravi M. Shanker , Walter C. Babcock , Dwayne T. Friesen , James A. S. Nightingale , Douglas A. Lorenz
CPC分类号： A61K47/38 , A61K9/146 , A61K9/1629 , A61K9/1652 , A61K31/135 , A61K31/404 , A61K31/4178 , A61K31/4375 , A61K31/496 , A61K31/517
摘要： A drug in a solubility-improved form is combined with a concentration-enhancing polymer in a sufficient amount so that the combination provides substantially enhanced drug concentration in a use environment relative to a control comprising the same amount of the same solubility-improved form of drug without the concentration-enhancing polymer.
-
5.发明授权公开(公告)号：US07235259B2
公开(公告)日：2007-06-26
申请号：US10066091
申请日：2002-02-01
申请人： Marshall D. Crew , William J. Curatolo , Dwayne T. Friesen , Michael Jon Gumkowski , Douglas A. Lorenz , James A. S. Nightingale , Roger B. Ruggeri , Ravi M. Shanker
发明人： Marshall D. Crew , William J. Curatolo , Dwayne T. Friesen , Michael Jon Gumkowski , Douglas A. Lorenz , James A. S. Nightingale , Roger B. Ruggeri , Ravi M. Shanker
CPC分类号： A61K31/4196 , A61K9/146 , A61K9/1635 , A61K9/1641 , A61K9/1652 , A61K31/41 , A61K31/47
摘要： A pharmaceutical composition comprises a solid amorphous dispersion of a cholesteryl ester transfer protein inhibitor and a concentration-enhancing polymer.
摘要翻译： 药物组合物包含胆固醇酯转移蛋白抑制剂和浓度增强聚合物的固体无定形分散体。
-
公开(公告)号：US07115279B2
公开(公告)日：2006-10-03
申请号：US09918127
申请日：2001-07-30
申请人： William J. Curatolo , Dwayne T. Friesen , Michael J. Gumkowski , Douglas A. Lorenz , James A. S. Nightingale , Roger B. Ruggeri , Ravi M. Shanker
发明人： William J. Curatolo , Dwayne T. Friesen , Michael J. Gumkowski , Douglas A. Lorenz , James A. S. Nightingale , Roger B. Ruggeri , Ravi M. Shanker
CPC分类号： A61K9/1652 , A61K9/146 , A61K9/1635 , A61K31/4196 , A61K31/47
摘要： A pharmaceutical composition comprises a solid amorphous dispersion of a cholesteryl ester transfer protein inhibitor and a concentration-enhancing polymer.
-
公开(公告)号：US08389011B2
公开(公告)日：2013-03-05
申请号：US13494668
申请日：2012-06-12
申请人： Marshall D. Crew , William J. Curatolo , Dwayne T. Friesen , Michael Jon Gumkowski , Douglas A. Lorenz , James A. S. Nightingale , Roger B. Ruggeri , Ravi M. Shanker
发明人： Marshall D. Crew , William J. Curatolo , Dwayne T. Friesen , Michael Jon Gumkowski , Douglas A. Lorenz , James A. S. Nightingale , Roger B. Ruggeri , Ravi M. Shanker
IPC分类号： A61K9/14 , A61K31/135 , A61K31/47 , A61K47/32
CPC分类号： A61K9/1652 , A61K9/146 , A61K9/1635 , A61K31/4196 , A61K31/47
摘要： A pharmaceutical composition comprises a solid amorphous dispersion of a cholesteryl ester transfer protein inhibitor and a concentration-enhancing polymer.
-
公开(公告)号：US20120259022A1
公开(公告)日：2012-10-11
申请号：US13527536
申请日：2012-06-19
申请人： William J. Curatolo , Ravi M. Shanker , Walter C. Babcock , Dwayne T. Friesen , James A. S. Nightingale , Douglas A. Lorenz
发明人： William J. Curatolo , Ravi M. Shanker , Walter C. Babcock , Dwayne T. Friesen , James A. S. Nightingale , Douglas A. Lorenz
IPC分类号： A61K47/38 , A61K47/40 , A61P9/12 , A61P25/22 , A61P25/28 , A61P25/08 , A61P11/14 , A61P35/00 , A61P25/20 , A61P3/04 , A61K47/32 , A61P7/02
CPC分类号： A61K47/38 , A61K9/146 , A61K9/1629 , A61K9/1652 , A61K31/135 , A61K31/404 , A61K31/4178 , A61K31/4375 , A61K31/496 , A61K31/517
摘要： A drug in a solubility-improved form is combined with a concentration-enhancing polymer in a sufficient amount so that the combination provides substantially enhanced drug concentration in a use environment relative to a control comprising the same amount of the same solubility-improved form of drug without the concentration-enhancing polymer.
摘要翻译： 将溶解度改善形式的药物与足够量的浓度增强聚合物组合，使得组合在使用环境中相对于包含相同量的相同溶解度改善形式的药物的对照提供了显着增强的药物浓度 没有浓度增强聚合物。
-
9.发明授权公开(公告)号：US08197848B2
公开(公告)日：2012-06-12
申请号：US11799447
申请日：2007-04-30
申请人： Marshall D. Crew , William J. Curatolo , Dwayne T. Friesen , Michael J. Gumkowski , Douglas A. Lorenz , James A. S. Nightingale , Roger B. Ruggeri , Ravi M. Shanker
发明人： Marshall D. Crew , William J. Curatolo , Dwayne T. Friesen , Michael J. Gumkowski , Douglas A. Lorenz , James A. S. Nightingale , Roger B. Ruggeri , Ravi M. Shanker
IPC分类号： A61K9/14 , A61K31/135 , A61K31/47 , A61K47/32
CPC分类号： A61K9/1652 , A61K9/146 , A61K9/1635 , A61K31/4196 , A61K31/47
摘要： A pharmaceutical composition comprises a solid amorphous dispersion of a cholesteryl ester transfer protein inhibitor and a concentration-enhancing polymer.
摘要翻译： 药物组合物包含胆固醇酯转移蛋白抑制剂和浓度增强聚合物的固体无定形分散体。
-
公开(公告)号：US20110294902A1
公开(公告)日：2011-12-01
申请号：US13208305
申请日：2011-08-11
申请人： William J. CURATOLO , Ravi M. Shanker , Walter C. Babccck , Dwayne T. Friesen , James A.S. Nightingale , Douglas A. Lorenz
发明人： William J. CURATOLO , Ravi M. Shanker , Walter C. Babccck , Dwayne T. Friesen , James A.S. Nightingale , Douglas A. Lorenz
IPC分类号： A61K47/38 , A61P9/12 , A61P25/22 , A61P25/08 , A61P11/14 , A61P35/00 , A61P29/00 , A61P25/18 , A61P3/04 , A61P25/24 , A61P25/28 , A61P25/20 , A61P25/16 , A61P31/00 , A61P31/04 , A61P31/10 , A61P31/12 , A61P37/00 , A61K47/32
CPC分类号： A61K47/38 , A61K9/146 , A61K9/1629 , A61K9/1652 , A61K31/135 , A61K31/404 , A61K31/4178 , A61K31/4375 , A61K31/496 , A61K31/517
摘要： A drug in a solubility-improved form is combined with a concentration-enhancing polymer in a sufficient amount so that the combination provides substantially enhanced drug concentration in a use environment relative to a control comprising the same amount of the same solubility-improved form of drug without the concentration-enhancing polymer.
摘要翻译： 将溶解度改善形式的药物与足够量的浓度增强聚合物组合，使得组合在使用环境中相对于包含相同量的相同溶解度改善形式的药物的对照提供了显着增强的药物浓度 没有浓度增强聚合物。
-
-
-
-
-
-
-
-
-
搜索结果
97 条记录 (耗时 0.055 秒)
